Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
Electra Therapeutics (ETRA) management will present at the Jefferies Global Healthcare Conference in London on November 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Electra Therapeutics (ETRA) management will present at the Jefferies Global Healthcare Conference in London on November 18, 2026. The presentation is scheduled for 1:00 p.m. GMT. A live webcast will be available in the Investors section at ir.electra-therapeutics.com, with a replay available after the event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc. (NASDAQ: ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced that management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026 at 1:00 p.m. GMT.
A live webcast of the presentation will be available in the Investors section of Electra’s website at ir.electra-therapeutics.com and a replay will be available following the event.
About Electra Therapeutics
Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function. The company’s lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory T-cell and natural-killer cell malignancies. ELA822, the company’s second clinical-stage product candidate, is a novel SIRPγ-specific antibody being developed for a broad range of chronic T cell-mediated immune and inflammatory diseases. For more information, please visit electra-therapeutics.com and follow us on LinkedIn.
Contacts:
Investor Contact:
Renee Leck, THRUST
Renee@thrustsc.com
Media Contact:
Sarah Sutton, THRUST
sarah@thrustsc.com
